Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer

Restricted access

Appendiceal malignancies are rare and represent 1% of intestinal tumors in the United States. The role and efficacy of modern systemic therapy in advanced appendiceal adenocarcinoma has not been established. This study analyzed patients with recurrent or metastatic appendiceal adenocarcinoma in the database for Colorectal Cancer (CRC; 2005-2012). This database tracks longitudinal care for patients treated at 8 specialty centers across the Unites States. Study objectives were to describe and evaluate the efficacy of systemic therapy and investigate relationships with clinicopathologic features. Cox regression analysis was performed to identify predictors of progression-free survival (PFS) and overall survival (OS). Of 248 patients with advanced appendiceal carcinoma, 112 (45%) received systemic therapy for measurable disease and are the focus of this report. The most common chemotherapy regimens included FOLFOX with or without bevacizumab (n=39 and n=37, respectively), FOLFIRI (n=15), and single-agent fluoro-pyrimidine (n=10). Among 99 patients evaluable for best response, 39 experienced a response (response rate [RR], 39%) and 36 (36%) had stable disease. The median PFS was 1.2 years (95% CI, 1.0-1.8) and median OS was 2.1 years (95% CI, 1.6-2.3). Patients with non-mucinous histology or high-grade tumors and those who underwent nondebulking surgery had worse PFS and OS. Treatment of advanced appendiceal adenocarcinoma at NCCN Member Institutions commonly incorporates agents used for CRC. RR, PFS, and OS are comparable to those achieved in the treatment of metastatic CRC. Poor prognostic factors include nonmucinous histology or high-grade tumors and history of nondebulking surgery.

Correspondence: Mohamedtaki A. Tejani, MD, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642. E-mail: mohamed_tejani@urmc.rochester.edu

Deceased.

  • 1.

    Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer J Clin 2012;62:1029.

  • 2.

    Connor S, Hanna G, Frizelle F. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum 1998;41:7580.

    • Search Google Scholar
    • Export Citation
  • 3.

    McCusker M, Cote T, Clegg L, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the Surveillance, Epidemiology, and End-Results program 1973-1998. Cancer 2002;94:33073312.

    • Search Google Scholar
    • Export Citation
  • 4.

    Smith J, Kemeny N, Caldwell C. Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1992;70:396401.

    • Search Google Scholar
    • Export Citation
  • 5.

    Gough D, Donohue J, Schutt A. Pseudomyxoma peritonei: Long-term patient survival with an aggressive regional approach. Ann Surg 1994;219:112119.

    • Search Google Scholar
    • Export Citation
  • 6.

    Baratti D, Kusamura S, Nonaka D. Pseudomyxoma peritonei: clinical, pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2008;15:526534.

    • Search Google Scholar
    • Export Citation
  • 7.

    Shapiro J, Chase J, Wolff R. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin. Cancer 2010;116:316322.

    • Search Google Scholar
    • Export Citation
  • 8.

    Lieu CH, Lambert LA, Wolff RA. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol 2012;23:652658.

    • Search Google Scholar
    • Export Citation
  • 9.

    Farquharson AL, Pranesh N, Witham G. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer 2008;99:591596.

    • Search Google Scholar
    • Export Citation
  • 10.

    Song X, Zhao Z, Barber B. Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics. Curr Med Res Opin 2011;27:123130.

    • Search Google Scholar
    • Export Citation
  • 11.

    Love N, Haller DG. Patterns of care in medical oncology: management of cancer of the colon and rectum in the adjuvant and metastatic settings. Available at www.researchtopractice.com. 2008;5:1.

    • Search Google Scholar
    • Export Citation
  • 12.

    Benson AB III, Venook AP, Bekaii-Saab T. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 3, 2014. Available at: NCCN.org. Accessed June 13, 2014.

    • Search Google Scholar
    • Export Citation
  • 13.

    Saltz LB, Clarke S, Diaz-Rubio E. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:20132019.

    • Search Google Scholar
    • Export Citation
  • 14.

    Nitecki SS, Wolff BG, Schlinkert R. The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg 1994;219:5160.

    • Search Google Scholar
    • Export Citation
  • 15.

    Cortina R, McCormick K, Kolm P. Management and prognosis of adenocarcinoma of the appendix. Dis Colon Rectum 1995;38:848.

  • 16.

    Kabbani W, Houlihan PS, Luthra R. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathologic features but similar genetic alterations. Mod Pathol 2002;15:599.

    • Search Google Scholar
    • Export Citation
  • 17.

    Sugarbaker P, Zhu B, Sese G. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 1993;36:233.

    • Search Google Scholar
    • Export Citation
  • 18.

    Sugarbaker P, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727731.

    • Search Google Scholar
    • Export Citation
  • 19.

    Niland JC. NCCN outcomes research database: data collection via the Internet. Oncology (Williston Park) 2000;14:100103.

  • 20.

    Rajput A, Romanus D, Weiser MR. Meeting the 12 lymph node benchmark in colon cancer. J Surg Oncol 2010;102:39.

  • 21.

    Sanoff HK, Carpenter WR, Martin CF. Comparative effectiveness of oxaliplatin vs. non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 2012;104:211227.

    • Search Google Scholar
    • Export Citation
  • 22.

    LaCasce AS, Vandergrift JL, Rodriguez MA. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012;119:20932099.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1220 1009 57
PDF Downloads 238 186 18
EPUB Downloads 0 0 0